, Volume 19, Issue 2, pp 93–96 | Cite as

The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects

  • A. M. Molloy
  • J. Ardill
  • G. H. Tomkin


Gastric acid secretion and gastrointestinal hormone levels were measured in healthy non-diabetic subjects after metformin treatment (1.5 g/day). The maximum acid output was increased from 15.7 ±3.9 mmol/h (mean±SEM) to 30.0±7.1 mmol/h (p < 0.05) and the peak acid output was increased from 16.4±4.1 mmol/h to 31.7±7.2 mmol/h (p < 0.05) after two weeks treatment. Serum insulin, gastric inhibitory polypeptide and secretin levels were normal. After treatment for one week, however, there was a significant increase in fasting vasoactive intestinal peptide (VIP) from 83±6 ng/l to 102±9 ng/l (p < 0.02) and in stimulated VIP from 58±5 ng/l to 79±5 ng/l (p < 0.05). Stimulated glucagon-like immunoreactivity (GLI) was also increased from 82±10 ng/l to 174±24 ng/l (p < 0.01) after one week's treatment. It is suggested that metformin acts as a eak histamine agonist.

Key words

Metformin biguanides gastric acid secretion histamine gastrin insulin vasoactive intestinal peptide (VIP) gastric inhibitory polypeptide (GIP) secretin glucagon-like immunoreactivity (GLI) 


  1. 1.
    Caspary WF (1977) Biguanides and intestinal absorptive function. Acta Hepatogastroenterol (Stuttg) 24: 473–480Google Scholar
  2. 2.
    Bloom SR (1977) Gastrointestinal hormones. Int Rev Physiol 12: 72–103Google Scholar
  3. 3.
    Multicentre Pilot Study (1967) Pentagastrin as a stimulant of maximal gastric acid response in man. Lancet I: 291–295Google Scholar
  4. 4.
    Tomkin GH (1973) Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. Br Med J III: 673–675Google Scholar
  5. 5.
    Hall H, Ramachander G, Glassman FM (1968) Tissue distribution and excretion of phenformin in normal and diabetic animals. Ann N Y Acad Sci 148: 601–611Google Scholar
  6. 6.
    Durant GJ, Parsons ME, Black JW (1975) Potential histamine H2-receptor antagonists (2) N-alpha guanylhistamine. J Med Chem 18: 830–833Google Scholar
  7. 7.
    Ash ASF, Schild HO (1966) Receptors mediating some actions of histamine. Br J Pharmacol 27: 427–439Google Scholar
  8. 8.
    Diniz RS, Abraham GJS, Ahmed SS (1972) Anti-gastric acid secretory effect of phenformin — a preliminary report. Eur J Pharmacol 19: 389–390Google Scholar
  9. 9.
    Mayer G, Arnold R, Feurle G, Fuchs K, Ketterer H, Track NS, Creutzfeldt W (1974) Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenterol 9: 703–710Google Scholar
  10. 10.
    Czyzyk A, Heding LG, Malczewski B, Miedzinska E (1975) The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics. Diabetologia 11: 129–134Google Scholar
  11. 11.
    Humphreys WG, Parks TG, Buchanan KD, Love AHG (1977) Effect of phenformin on provoked dumping in man. Gut 18: A956Google Scholar
  12. 12.
    Waldman DB, Gardner JD, Makhlouf GM (1977) In: Bonfils S (ed) First International Symposium on Hormonal Receptors in Digestive Tract Physiology, INSERM Symposium. Elsevier/North-Holland, Biomedical Press, New York, p 507–508Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • A. M. Molloy
    • 1
    • 2
    • 3
  • J. Ardill
    • 1
    • 2
  • G. H. Tomkin
    • 1
    • 2
  1. 1.Metabolic UnitAdelaide HospitalDublinIreland
  2. 2.Department of MedicineQueens UniversityBelfastNorthern Ireland
  3. 3.Department of BiochemistryTrinity CollegeDublin 2Ireland

Personalised recommendations